CellSync Biosciences

CellSync Biosciences is a biotechnology company developing a proprietary platform to synchronize cell populations for the production of advanced cell therapies. By ensuring that therapeutic cells are in a uniform, high-potency state during manufacturing and delivery, the company aims to improve the efficacy, consistency, and safety of treatments such as CAR-T and NK cell therapies. Their technology addresses the inherent heterogeneity of primary cell starting materials, which is a major bottleneck in the scalability and reliability of cell-based medicines. CellSync Biosciences is headquartered in San Diego and was a participant in the IndieBio (SOSV) accelerator program. The company's approach has the potential to transform the manufacturing landscape for next-generation immunotherapies.